Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon

T. Gjørup, O. J. Hartling, H. Kelbæk, S. L. Nielsen

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review

    Abstrakt

    In a controlled double blind trial the symptomatic effect of the calcium channel blocker nisoldipine was assessed in 19 patients with idiopathic Raynaud's phenomenon. Nisoldipine significantly reduced the frequency of attacks (p<0.05), whilst having a non-significant tendency (p<0.10) to reduce the severity of attacks. Side-effects were uncommon. It is concluded that nisoldipine is a promising agent for the symptomatic treatment of idiopathic Raynaud's phenomenon.

    OriginalsprogEngelsk
    Sider (fra-til)387-389
    Antal sider3
    TidsskriftEuropean Journal of Clinical Pharmacology
    Vol/bind31
    Udgave nummer4
    DOI
    StatusUdgivet - 1 jul. 1986

    Fingeraftryk

    Udforsk hvilke forskningsemner 'Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon' indeholder.

    Citationsformater